TRCT
REGN icon

Tower Research Capital (TRC)’s Regeneron Pharmaceuticals REGN Stock Holding History

Tower Research Capital (TRC)’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.38M Sell
4,378
-2,346
-35% -$1.8M 0.09% 229
2025
Q4 		$5.19M Buy
6,724
+1,214
+22% +$824K 0.13% 140
2025
Q3 		$3.1M Buy
5,510
+4,563
+482% +$2.58M 0.09% 203
2025
Q2 		$497K Sell
947
-4,150
-81% -$2.32M 0.01% 989
2025
Q1 		$3.23M Sell
5,097
-3,375
-40% -$2.32M 0.1% 170
2024
Q4 		$6.03M Buy
8,472
+4,978
+142% +$4.18M 0.12% 128
2024
Q3 		$3.67M Sell
3,494
-6,337
-64% -$7.05M 0.1% 137
2024
Q2 		$10.3M Buy
9,831
+1,307
+15% +$1.27M 0.17% 81
2024
Q1 		$8.2M Sell
8,524
-10,029
-54% -$9.54M 0.2% 74
2023
Q4 		$16.3M Buy
18,553
+13,392
+259% +$11M 0.2% 86
2023
Q3 		$4.25M Sell
5,161
-5,787
-53% -$4.55M 0.13% 133
2023
Q2 		$7.87M Buy
10,948
+8,910
+437% +$6.87M 0.26% 44
2023
Q1 		$1.68M Sell
2,038
-1,648
-45% -$1.24M 0.05% 240
2022
Q4 		$2.66M Sell
3,686
-17,163
-82% -$12.7M 0.11% 130
2022
Q3 		$14.4M Buy
20,849
+1,644
+9% +$1.03M 0.23% 71
2022
Q2 		$11.4M Sell
19,205
-13,274
-41% -$8.63M 0.25% 65
2022
Q1 		$22.7M Buy
32,479
+18,450
+132% +$11.7M 0.22% 88
2021
Q4 		$8.86M Buy
14,029
+7,909
+129% +$4.86M 0.15% 104
2021
Q3 		$3.7M Buy
6,120
+1,647
+37% +$1.02M 0.09% 138
2021
Q2 		$2.5M Sell
4,473
-11,412
-72% -$5.78M 0.07% 246
2021
Q1 		$7.52M Buy
15,885
+12,498
+369% +$6.08M 0.13% 143
2020
Q4 		$1.64M Sell
3,387
-1,478
-30% -$798K 0.05% 287
2020
Q3 		$2.72M Buy
4,865
+333
+7% +$202K 0.03% 236
2020
Q2 		$2.83M Buy
+4,532
New +$2.57M 0.12% 141
2020
Q1 		– Sell
-1,811
Closed -$680K – 3750
2019
Q4 		$680K Buy
1,811
+321
+22% +$108K 0.06% 193
2019
Q3 		$413K Sell
1,490
-3,350
-69% -$991K 0.03% 651
2019
Q2 		$1.51M Buy
4,840
+2,922
+152% +$973K 0.1% 153
2019
Q1 		$788K Buy
1,918
+1,523
+386% +$627K 0.05% 370
2018
Q4 		$148K Sell
395
-1,548
-80% -$567K 0.01% 793
2018
Q3 		$785K Sell
1,943
-2,271
-54% -$864K 0.06% 290
2018
Q2 		$1.45M Buy
+4,214
New +$1.32M 0.08% 240
2018
Q1 		– Sell
-286
Closed -$108K – 3735
2017
Q4 		$108K Sell
286
-191
-40% -$77.4K 0.01% 832
2017
Q3 		$213K Buy
+477
New +$227K 0.02% 717
2017
Q2 		– Sell
-26
Closed -$10K – 3308
2017
Q1 		$10K Sell
26
-74
-74% -$27.4K ﹤0.01% 1775
2016
Q4 		$37K Buy
100
+99
+9,900% +$37.6K ﹤0.01% 1637
2016
Q3 		$0 Sell
1
-219
-100% -$87.8K ﹤0.01% 4291
2016
Q2 		$77K Sell
220
-209
-49% -$80.5K 0.01% 1271
2016
Q1 		$155K Buy
+429
New +$177K 0.02% 382
2015
Q4 		– Sell
-248
Closed -$115K – 4956
2015
Q3 		$115K Sell
248
-462
-65% -$248K 0.01% 487
2015
Q2 		$362K Sell
710
-1,048
-60% -$511K 0.03% 192
2015
Q1 		$794K Buy
1,758
+1,723
+4,923% +$730K 0.1% 128
2014
Q4 		$14K Sell
35
-2,436
-99% -$958K ﹤0.01% 1853
2014
Q3 		$891K Buy
2,471
+2,381
+2,646% +$798K 0.1% 177
2014
Q2 		$25K Buy
+90
New +$26.7K ﹤0.01% 1712
2014
Q1 		– Sell
-2,840
Closed -$781K – 4839
2013
Q4 		$781K Buy
2,840
+1,894
+200% +$545K 0.13% 110
2013
Q3 		$296K Buy
+946
New +$249K 0.03% 519

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Tower Research Capital (TRC)'s REGN Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Regeneron Pharmaceuticals (REGN) stake by 35% in Q1 2026, selling an estimated $1.8M and leaving 4,378 shares worth $3.38M. The position accounts for 0.09% of the portfolio, ranked #229.

Tower Research Capital (TRC) first reported a position in REGN in Q3 2013 and has held it in 46 quarters since. The position peaked at $22.7M in Q1 2022. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Tower Research Capital (TRC) held 4,378 shares of Regeneron Pharmaceuticals worth $3.38M as of Q1 2026.
  • Tower Research Capital (TRC) sold 2,346 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.8M.
  • Regeneron Pharmaceuticals made up 0.09% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #229 holding.
  • Tower Research Capital (TRC) first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 46 quarters since.
  • Tower Research Capital (TRC)'s Regeneron Pharmaceuticals position peaked at $22.7M in Q1 2022.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.